Hypoxia‐Inducible Factor‐1 as a Therapeutic Target in Endometrial Cancer Management
Open Access
- 1 January 2010
- journal article
- review article
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2010 (1) , 580971
Abstract
In the Western world, endometrial cancer (EC) is the most common malignant tumor of the female genital tract. Solid tumors like EC outgrow their vasculature resulting in hypoxia. Tumor hypoxia is important because it renders an aggressive phenotype and leads to radio‐ and chemo‐therapy resistance. Hypoxia‐inducible factor‐1α (HIF‐1α) plays an essential role in the adaptive cellular response to hypoxia and is associated with poor clinical outcome in EC. Therefore, HIF‐1 could be an attractive therapeutic target. Selective HIF‐1 inhibitors have not been identified. A number of nonselective inhibitors which target signaling pathways upstream or downstream HIF‐1 are known to decrease HIF‐1α protein levels. In clinical trials for the treatment of advanced and/or recurrent EC are the topoisomerase I inhibitor Topotecan, mTOR‐inhibitor Rapamycin, and angiogenesis inhibitor Bevacizumab. Preliminary data shows encouraging results for these agents. Further work is needed to identify selective HIF‐1 inhibitors and to translate these into clinical trials.Keywords
This publication has 70 references indexed in Scilit:
- Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migrationInternational Journal of Cancer, 2007
- The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal CarcinomaClinical Cancer Research, 2007
- An investigation of relationships between hypoxia-inducible factor-1α gene polymorphisms and ovarian, cervical and endometrial cancersCancer Detection Prevention, 2007
- Oncological implications of hypoxia inducible factor-1α (HIF-1α) expressionCancer Treatment Reviews, 2006
- Hypoxia-inducible factor-1α expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomasOncogene, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Mutation analysis of the HIF-1α oxygen-dependent degradation domain in invasive breast cancerCancer Genetics and Cytogenetics, 2005
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Regulation of Mammalian O2Homeostasis by Hypoxia-Inducible Factor 1Annual Review of Cell and Developmental Biology, 1999
- Activation of Hypoxia-inducible Transcription Factor Depends Primarily upon Redox-sensitive Stabilization of Its α SubunitJournal of Biological Chemistry, 1996